Evidence map›Paper›PMID 40270824›Full record

ArticleFrontiers in microbiology2025

Improved antibacterial activity of a sustained-release biocompatible nanofilm for treating

Feifei Lu, Guoxiu Lu, Zhiguo Wang, Wenzhua Wei, Jingjing Chen, Hailin Zheng, Xuesong Liu, Yan Ye, Shuling Liu, Yuxiang Lin and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Feifei Lu *College of Medicine and Biological Information Engineering, Northeastern University, Shenyang, Liaoning, China.
Guoxiu Lu *College of Medicine and Biological Information Engineering, Northeastern University, Shenyang, Liaoning, China.
Zhiguo WangDepartment of Nuclear Medicine, General Hospital of Northern Theater Command, Shenyang, China.
Wenzhua WeiNational Engineering Research Centre of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Third Military Medical University, Chongqing, China.
Jingjing ChenNational Engineering Research Centre of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Third Military Medical University, Chongqing, China.
Hailin ZhengNational Engineering Research Centre of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Third Military Medical University, Chongqing, China.
Xuesong LiuNational Engineering Research Centre of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Third Military Medical University, Chongqing, China.
Yan YeNational Engineering Research Centre of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Third Military Medical University, Chongqing, China.
Shuling LiuNational Engineering Research Centre of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Third Military Medical University, Chongqing, China.
Yuxiang LinDepartment of Nuclear Medicine, General Hospital of Northern Theater Command, Shenyang, China.
Yuxin LiuDepartment of Nuclear Medicine, General Hospital of Northern Theater Command, Shenyang, China.
Zhanhua BiDepartment of Nuclear Medicine, General Hospital of Northern Theater Command, Shenyang, China.
Quanming ZouNational Engineering Research Centre of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Third Military Medical University, Chongqing, China.
Guoxu ZhangCollege of Medicine and Biological Information Engineering, Northeastern University, Shenyang, Liaoning, China.
Hongwu SunNational Engineering Research Centre of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Third Military Medical University, Chongqing, China.
Yanan TongDepartment of Nuclear Medicine, General Hospital of Northern Theater Command, Shenyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: The primary goal of this research was to design a useful and biocompatible nanofilm system (CNF) encapsulating chlorhexidine acetate (CHX) for wounds that is endowed with antibacterial and anti-inflammatory activities and promotes wound healing. Methods: The nanofilm system was developed on the basis of the successful preparation of its nanoemulsion and PVA-CS film system and then important properties of the nanofilm system, including its morphological and physicochemical characteristics, stability and safety, its antimicrobial efficacy against Results: These results of this nanofilm system revealed a good particle size (59.27 nm) and stable zeta potential (-15.2 mV) that are suitable for wound healing applications. Additionally, it was stable, exhibited long-term stability (24 months) and sustained release in simulated wound fluid. Results showed that this nanofilm does not induce dose-related toxic effects and displays a better antibacterial effect that occurs more quickly, two times greater than that of CHX Conclusions: These insights into multifunctional nanofilm designs for improved antibacterial effects and sustained release suggest promising clinical applications.

Indexed as

antibacterial effectmultidrug-resistant bacterialnanofilmPseudomonas aeruginosawound heal

Identifiers

PMID40270824
PMCPMC12015611

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.